A key dysregulation in breast cancer involves the overactivation of cyclin-dependent kinases 4 and 6 (CDK4/6) (Sherr et al., 2016; Watt and Goel, 2022; Fassl et al., 2022; Shanabag et al., 2025). Here, CDK4 is linked to breast carcinoma.